Clinical trial access depends on study criteria and site screening, while approved medical treatment requires a regulator-authorized product and clinician direction
A 39-amino-acid synthetic peptide with three non-coded residues does not come cheap to manufacture correctly, and that manufacturing complexity has created a landscape where quality varies wildly from one vendor to the next
For women experiencing GLP-1 facial changes, these treatments may complement approaches that reach deeper collagen structures
[DOI] [PMC free article] [PubMed] [Google Scholar] 75.Mukherjee S., Chellappa K., Moffitt A., Ndungu J., Dellinger R.W., Davis J.G., Agarwal B., Baur J.A
It cannot be legally prescribed through standard NHS or private prescribing routes at this time